AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04937582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)
Study NCT04937582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture
Study NCT04937582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric evaluation
Description: Psychiatric consultation if necessary
Study NCT06266858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fasting
Description: At the beginning of the study, the patients need to fast when receive UCG.
Study NCT05073718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid
Description: In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
Study NCT05073718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04884737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mepilex Border Flex® (MBF) dressing
Description: A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
Study NCT04937582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric evaluation
Description: Psychiatric consultation if necessary (before the end of their participation in the study)
Study NCT04897841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
Study NCT04897841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
Study NCT04897841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
Study NCT04897841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline
Description: post-surgical saline
Study NCT06027294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: A cuff will be inflated to a pressure of 225 mmHg.
Study NCT06027294 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic Conditioning
Description: A cuff will be inflated to a pressure of 225 mmHg.
Study NCT06180772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT FIRST
Description: High intensity sports drills and games
Study NCT04897841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: post-surgical saline
Study NCT06554925 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: The difference in males and females undergoing cardiac surgery of all types
Study NCT05647967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Each patient underwent ultrasound after admission of ICU.
Study NCT03915613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R
Description: The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Study NCT05058560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: tislelizumab, 200 mg IV Q3W, up to one year.
Study NCT03915613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluent
Description: The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose.
Study NCT05213715 — intervention group
Intervention type: OTHER
Intervention: assessment
Description: assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity
Study NCT04680871 — intervention group
Intervention type: DEVICE
Intervention: In-Ear Sensor
Description: The device will passively monitor participants' biometrics
Study NCT05754281 — intervention group
Intervention type: DEVICE
Intervention: 2nd Gen LabPatch Glucose Sensing System
Description: I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements
Study NCT06496958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation with an abdominal compression device
Description: For participants randomized to the intervention group, the back brace support belt, Maxbelt (me3 type, Nippon Sigmax Co., Tokyo, Japan), will be applied around the circumference of the lower abdomen. Five sizes of Maxbelt will be employed in this study. According to the manufacturer, the ultra small-size (XS-size) belt will be used in those patients with an abdominal circumference of 55 cm-65 cm, the small-size (S-size) belt will be used in those patients with an abdominal circumference of 65 cm-75 cm, the medium-size (M-size) belt will be used for a circumference of 75 cm-85 cm, the large-size (L-size) belt will be used for a circumference of 85 cm-95 cm, and the ultra large-size (XL-size) will be used for a circumference of 95 cm-105 cm. Once applied, participants will be asked to assess and confirm that the belt is fastened tightly but not uncomfortably.
Study NCT06496958 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO2 insufflation with a sham abdominal compression device
Description: The study coordinator will fit the sham device in a private bay alone with the patient. For participants randomized to the sham control group, a larger-sized Maxbelt with loose fitting will be used as a sham device. The L-size Maxbelt will be used in those patients with an abdominal circumference of 55 cm-71 cm, the XL-size Maxbelt will be used in in those patients with an abdominal circumference of 72 cm-88 cm, and the 2 XL-size Maxbelt will be used in in those patients with abdominal circumference 89 cm-105 cm.
Study NCT06496958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange colonoscopy
Description: In those patients assigned to the water exchange (WE) group, the air pump will be turned off during the insertion phase of colonoscopy, while the colon is irrigated with warm-to-touch distilled water or half normal saline using a flushing pump. The WE approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Any encountered air pockets will be aspirated to ensure optimal WE maneuvers in salvage cleaning.
Study NCT04419181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Dose: 75 mg/m2 q3w
Study NCT04419181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose: area under the concentration-time curve \[AUC\] 6 q3w
Study NCT04419181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
Study NCT04419181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Dose: 840-mg loading dose, 420-mg maintenance dose q3w
Study NCT04419181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Dose: 3.6mg/kg q3w
Study NCT04743765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated medical clearance and surgery
Description: Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
Study NCT06114329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL01211
Description: AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
Study NCT04789967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery
Description: Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
Study NCT04789967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
Study NCT04789967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Audiobook
Description: Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
Study NCT04865484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection of fibrostenotic area (>4cm)
Study NCT04865484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: Surgical resection of fibrostenotic area (>4cm)
Study NCT04865484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic stricturotomy
Description: Endoscopic stricturotomy of fibrostenotic area (≤4cm)
Study NCT04865484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strictureplasty
Description: Strictureplasty of fibrostenotic area (≤4cm)
Study NCT05589454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium tablets 80mg
Description: Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Study NCT05589454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium tablets 20mg
Description: Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Study NCT05104476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Description: Solution for infusion
Study NCT05148780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab Sample
Description: Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
Study NCT05039723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiesse, Xeomin, Belotero
Description: Rejuvenation with Radiesse, Xeomin, Belotero
Study NCT04710017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
Study NCT04710017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medroxyprogesterone Acetate 150 MG/ML
Description: will be given MPA at 150 mg once intramuscular injection
Study NCT04722094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Full periodontal chart
Description: A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
Study NCT04722094 — intervention group
Intervention type: OTHER
Intervention: Saliva sampling
Description: Saliva samples for miRNAs detection will be taken before starting the visit.
Study NCT04800224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Brazilian Green Propolis Extract
Description: 900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
Study NCT04800224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 900mg/day of Placebo for 10 days.
Study NCT05928364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal mucosa for proximal ureter stricture
Description: Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
Study NCT06052176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Infusion
Description: Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
Study NCT06052176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin Infusion
Description: Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
Study NCT06630091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: 150 mg once per day by PO
Study NCT06630091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 by IV
Study NCT06630091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by IV
Study NCT06630091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (max: 2 mg) by IV
Study NCT06630091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg by PO
Study NCT04967508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara® (Ustekinumab)
Description: Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
Study NCT04967508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17 (Proposed Ustekinumab Biosimilar)
Description: Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection.
Study NCT04967508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB17 (Proposed Ustekinumab Biosimilar)
Description: Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection.
Study NCT05104476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for infusion
Study NCT05580172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RH324
Description: polymolecular
Study NCT05362006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exopulse Mollii Suit
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more.
Study NCT05362006 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exopulse Mollii suit (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study NCT06484868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Study NCT05471375 — intervention group
Intervention type: OTHER
Intervention: Database Entry
Description: Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
Study NCT04676880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)
Description: Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
Study NCT06055439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHM-2101 CAR-T cells
Description: Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells
Study NCT05534100 — intervention group
Intervention type: DEVICE
Intervention: Biostrap EVO Wristband
Description: Participants in both groups will wear the Biostrap wearable device
Study NCT05804604 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical treatment of proximal femur fracture and blood sample test
Description: Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
Study NCT05804604 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample test
Description: Analysis of serum concentration of: SHBG, CTX - I, CK-MB
Study NCT06386562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program
Description: The internet-based parenting support program is based on social learning theory. A foundation is the Family Check-up program (FCU), which includes approaches from motivational interviewing (MI). The parenting support is also based on similar CBT-parenting strategies as in other evaluated face-to-face CBT-parenting support programs (e.g., Comet) as well as internet-based programs (e.g., iComet; ParentWeb).
Study NCT06386562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program with additional parental support
Description: The internet-based parenting program includes the same contents and chat-function as in the other condition. The focus for the digital/phone meetings is to explore potential questions, problem-solve around potential challenges, and motivate parents to practice strategies and complete modules.
Study NCT05982353 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PTFE application
Description: Polytetrafluoroethylene membrane used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
Study NCT05982353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin sponge
Description: gelatin sponge used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
Study NCT04976634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion
Study NCT04976634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD via oral tablet
Study NCT04976634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
Study NCT04845646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: 5mg/tablet
Study NCT04845646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg/capsule
Study NCT04845646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: 300mg/capsule
Study NCT06232655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.